Skip to content
2000
image of The Diverse Roles of Long Non-Coding RNA HOTTIP in Breast and Gynecological Cancer Progression

Abstract

Long non-coding RNAs (lncRNAs) play vital roles in the development and progression of various tumors through multiple mechanisms. Among these, HOTTIP (HOXA transcript at the distal tip) stands out as an intriguing candidate with diverse functions in several malignancies, including breast cancer and gynecologic cancers such as ovarian, cervical, and endometrial cancers, which are significant global health concerns. HOTTIP interacts with key signaling pathways associated with these cancers, including Wnt/β-catenin, PI3K/AKT, and MEK/ERK pathways, enhancing their activation and downstream effects. Its influence extends to crucial aspects of cancer biology, such as cell proliferation, apoptosis, migration, invasion, angiogenesis, and epithelial-mesenchymal transition (EMT). Additionally, HOTTIP plays a pivotal role in the pathogenesis of breast and gynecologic tumors by sponging various microRNAs (miRNAs) and regulating the expression of mRNAs involved in critical molecular processes. This dysregulation is often associated with poor clinical outcomes, advanced disease stages, and distant metastases. Understanding the functional roles of HOTTIP in these cancers is essential for developing targeted therapeutic strategies. This review aims to explore the emerging roles of HOTTIP in breast and gynecologic cancers.

Loading

Article metrics loading...

/content/journals/cmm/10.2174/0115665240336515241124151446
2025-01-06
2025-07-08
Loading full text...

Full text loading...

References

  1. Ekinci N. Karaman S.T. Basat O. Women’s knowledge levels in protection from gynecological cancers and affecting factors. Eur. Arch. Med. Res. 2023 39 4 262 268
    [Google Scholar]
  2. Pour F.K. Keivan M. Ghaedrahmati F. Saadati N. Moramezi F. Nikbakht R. Farzaneh M. Endometrial cancer stem cells related signaling pathways. Curr. Cancer Ther. Rev. 2023 19 4 284 291 10.2174/1573394719666230306145642
    [Google Scholar]
  3. Crosbie E.J. Kitson S.J. McAlpine J.N. Mukhopadhyay A. Powell M.E. Singh N. Endometrial cancer. Lancet 2022 399 10333 1412 1428 10.1016/S0140‑6736(22)00323‑3 35397864
    [Google Scholar]
  4. Gaona-Luviano P. Medina-Gaona L.A. Magaña-Pérez K. Epidemiology of ovarian cancer. Chin. Clin. Oncol. 2020 9 4 47 10.21037/cco‑20‑34 32648448
    [Google Scholar]
  5. Pimple S. Mishra G. Cancer cervix: Epidemiology and disease burden. Cytojournal 2022 19 21 10.25259/CMAS_03_02_2021 35510109
    [Google Scholar]
  6. Merlo S. Modern treatment of vulvar cancer. Radiol. Oncol. 2020 54 4 371 376 10.2478/raon‑2020‑0053 32960779
    [Google Scholar]
  7. Adams T.S. Rogers L.J. Cuello M.A. Cancer of the vagina: 2021 update. Int. J. Gynaecol. Obstet. 2021 155 S1 Suppl. 1 19 27 10.1002/ijgo.13867 34669198
    [Google Scholar]
  8. Abouali Gale Dari M. Anbiyaiee A. Moghanibashi M. Mohammad Jafari R. Moramezi F. Farzaneh M. Exploring the Evolving Significance of lncRNA TUG1-mediated Signaling Pathways in Breast Cancer. Curr. Signal Transduct. Ther. 2024 19 1 e190124225822 10.2174/0115743624264761231212055008
    [Google Scholar]
  9. Khan M.M. Yalamarty S.S.K. Rajmalani B.A. Filipczak N. Torchilin V.P. Recent strategies to overcome breast cancer resistance. Crit. Rev. Oncol. Hematol. 2024 197 104351 10.1016/j.critrevonc.2024.104351 38615873
    [Google Scholar]
  10. Łukasiewicz S. Czeczelewski M. Forma A. Baj J. Sitarz R. Stanisławek A. Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. Cancers 2021 13 17 4287 10.3390/cancers13174287 34503097
    [Google Scholar]
  11. Son J. Carr C. Yao M. Radeva M. Priyadarshini A. Marquard J. Michener C.M. AlHilli M. Endometrial cancer in young women: Prognostic factors and treatment outcomes in women aged ≤40 years. Int. J. Gynecol. Cancer 2020 30 5 631 639 10.1136/ijgc‑2019‑001105 32213530
    [Google Scholar]
  12. Speiser D. Bick U. Primary prevention and early detection of hereditary breast cancer. Breast Care 2023 18 6 448 454 10.1159/000533391 38125920
    [Google Scholar]
  13. Ponti G. De Angelis C. Ponti R. Pongetti L. Losi L. Sticchi A. Tomasi A. Ozben T. Hereditary breast and ovarian cancer: From genes to molecular targeted therapies. Crit. Rev. Clin. Lab. Sci. 2023 60 8 640 650 10.1080/10408363.2023.2234488 37455374
    [Google Scholar]
  14. Sokolova A. Johnstone K.J. McCart Reed A.E. Simpson P.T. Lakhani S.R. Hereditary breast cancer: Syndromes, tumour pathology and molecular testing. Histopathology 2023 82 1 70 82 10.1111/his.14808 36468211
    [Google Scholar]
  15. Bowden S.J. Doulgeraki T. Bouras E. Markozannes G. Athanasiou A. Grout-Smith H. Kechagias K.S. Ellis L.B. Zuber V. Chadeau-Hyam M. Flanagan J.M. Tsilidis K.K. Kalliala I. Kyrgiou M. Risk factors for human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer: An umbrella review and follow-up Mendelian randomisation studies. BMC Med. 2023 21 1 274 10.1186/s12916‑023‑02965‑w 37501128
    [Google Scholar]
  16. Keyvani V. Kheradmand N. Navaei Z.N. Mollazadeh S. Esmaeili S.A. Epidemiological trends and risk factors of gynecological cancers: An update. Med. Oncol. 2023 40 3 93 10.1007/s12032‑023‑01957‑3 36757546
    [Google Scholar]
  17. Golia D’Augè T. Giannini A. Bogani G. Di Dio C. Laganà A.S. Di Donato V. Salerno M.G. Caserta D. Chiantera V. Vizza E. Muzii L. D’Oria O. Prevention, screening, treatment and follow-up of gynecological cancers: state of art and future perspectives. Clin. Exp. Obstet. Gynecol. 2023 50 8 160 10.31083/j.ceog5008160
    [Google Scholar]
  18. Gitas G. Pados G. Laganà A.S. Guenther V. Ackermann J. Alkatout I. Role of laparoscopic hysterectomy in cervical and endometrial cancer: A narrative review. Minim. Invasive Ther. Allied Technol. 2023 32 1 1 11 10.1080/13645706.2022.2154166 36512487
    [Google Scholar]
  19. Hernandez-Zepeda M.L. Munro E.G. Caughey A.B. Bruegl A.S. Ovarian preservation compared to oophorectomy in premenopausal women with early-stage, low-grade endometrial Cancer: A cost-effectiveness analysis. Gynecol. Oncol. 2023 173 8 14 10.1016/j.ygyno.2023.03.021 37030073
    [Google Scholar]
  20. Lu Y. Chen J. Wei R. Lin W. Chen Y. Su Y. Liu L. Liang Y. Wei M. Application of robotic surgery and traditional laparoscopic surgery in lymph node dissection for gynecological cancer: A meta‑analysis. Oncol. Lett. 2023 25 5 175 10.3892/ol.2023.13761 37033101
    [Google Scholar]
  21. Hitova-Topkarova D Payakova V Kostova-Lefterova D Ivanova M Vasileva-Slaveva M Yordanov A Electronic brachytherapy for gynecological cancers - A systematic review. Rep. Pract. Oncol. Radiother. 2023 28 1 79 87
    [Google Scholar]
  22. Wysocki P.J. Łobacz M. Potocki P. Kwinta Ł. Michałowska-Kaczmarczyk A. Słowik A. Konopka K. Buda-Nowak A. Metronomic chemotherapy based on topotecan or topotecan and cyclophosphamide combination (CyTo) in advanced, pretreated ovarian cancer. Cancers 2023 15 4 1067 10.3390/cancers15041067 36831410
    [Google Scholar]
  23. Walsh C.S. Hacker K.E. Secord A.A. DeLair D.F. McCourt C. Urban R. Molecular testing for endometrial cancer: An SGO clinical practice statement. Gynecol. Oncol. 2023 168 48 55 10.1016/j.ygyno.2022.10.024 36399812
    [Google Scholar]
  24. Doghish A.S. Ali M.A. Elyan S.S. Elrebehy M.A. Mohamed H.H. Mansour R.M. Elgohary A. Ghanem A. Faraag A.H.I. Abdelmaksoud N.M. Moustafa H.A.M. miRNAs role in cervical cancer pathogenesis and targeted therapy: Signaling pathways interplay. Pathol. Res. Pract. 2023 244 154386 10.1016/j.prp.2023.154386 36868096
    [Google Scholar]
  25. Mikhanovskyi A. Kharchenko Y.V. Justification of the choice of hormone therapy for ovarian cancer. Infusion & Chemotherapy 2023 46 53
    [Google Scholar]
  26. Mobinikhaledi M. Faridzadeh A. Farkhondeh T. Pourhanifeh M.H. Samarghandian S. The roles of autophagy-related mirnas in gynecologic tumors: A review of current knowledge for possible targeted therapy. Curr. Mol. Med. 2024 24 10 1269 1281 10.2174/0115665240263059231002093454 39300715
    [Google Scholar]
  27. Lampropoulou D.I. Papadimitriou M. Papadimitriou C. Filippou D. Kourlaba G. Aravantinos G. Gazouli M. The role of EMT-related lncRNAs in ovarian cancer. Int. J. Mol. Sci. 2023 24 12 10079 10.3390/ijms241210079 37373222
    [Google Scholar]
  28. Razavi Z.S. Tajiknia V. Majidi S. Ghandali M. Mirzaei H.R. Rahimian N. Hamblin M.R. Mirzaei H. Gynecologic cancers and non-coding RNAs: Epigenetic regulators with emerging roles. Crit. Rev. Oncol. Hematol. 2021 157 103192 10.1016/j.critrevonc.2020.103192 33290823
    [Google Scholar]
  29. GAO Y. Expression and clinical significance of long non-coding RNA HOTTIP in tissues of patients with endometrial carcinoma. Zhongguo Zhongliu Shengwu Zhiliao Zazhi 2020 1378 1382
    [Google Scholar]
  30. Najafi S. Ghaedrahmati F. Abouali Gale Dari M. Farzaneh M. Mohammad Jafari R. The regulatory role of circular RNAs as miRNA sponges in cervical cancer. Curr. Signal Transduct. Ther. 2023 18 3 e241123223777 10.2174/0115743624273536231105142321
    [Google Scholar]
  31. Zou T. Wang P.L. Gao Y. Liang W.T. Long noncoding RNA HOTTIP is a significant indicator of ovarian cancer prognosis and enhances cell proliferation and invasion. Cancer Biomark. 2019 25 2 133 139 10.3233/CBM‑181727 30452402
    [Google Scholar]
  32. Zhu S-K. Zhang Y. Xu T. Yang C. Zhong S. Ran Q. Prognostic value of long non-coding RNA HOTTIP as a novel biomarker in various cancers: A meta-analysis. Tumour Biol. 2017 39 1010428317715530
    [Google Scholar]
  33. Abdi E. Latifi-Navid S. Zahri S. Kholghi-Oskooei V. Mostafaiy B. Yazdanbod A. Pourfarzi F. SNP-SNP interactions of oncogenic long non-coding RNAs HOTAIR and HOTTIP on gastric cancer susceptibility. Sci. Rep. 2020 10 1 16763 10.1038/s41598‑020‑73682‑0 33028884
    [Google Scholar]
  34. Lv Z. Xu Q. Sun L. Wen J. Fang X. Xing C. Yuan Y. Four novel polymorphisms in long non-coding RNA HOTTIP are associated with the risk and prognosis of colorectal cancer. Biosci. Rep. 2019 39 5 BSR20180573 10.1042/BSR20180573 30940774
    [Google Scholar]
  35. Sun Y. Hu B. Wang Q. Ye M. Qiu Q. Zhou Y. Zeng F. Zhang X. Guo Y. Guo L. Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216a. Cell Death Dis. 2018 9 2 85 10.1038/s41419‑017‑0113‑5 29367594
    [Google Scholar]
  36. Singh A.P. Luo H. Matur M. Eshelman M.A. Hamamoto K. Sharma A. Lesperance J. Huang S. A coordinated function of lncRNA HOTTIP and miRNA-196b underpinning leukemogenesis by targeting FAS signaling. Oncogene 2022 41 5 718 731 10.1038/s41388‑021‑02127‑3 34845377
    [Google Scholar]
  37. Brewer G. Wilson G.M. Introduction to RNA and Cancer. RNA-based Mechanisms in Cancer. World Scientific 2024 1 12
    [Google Scholar]
  38. Liu T. Wang H. Yu H. Bi M. Yan Z. Hong S. Li S. The long non-coding RNA HOTTIP is highly expressed in colorectal cancer and enhances cell proliferation and invasion. Mol. Ther. Nucleic Acids 2020 19 612 618 10.1016/j.omtn.2019.12.008 31945724
    [Google Scholar]
  39. Hao Y. Zhu G. Yu L. Ren Z. Zhou W. Zhang P. FOXO3-activated HOTTIP sequesters MiR-615-3p away from COL2A1 to mitigate intervertebral disc degeneration. Am. J. Pathol. 2023 37981220
    [Google Scholar]
  40. Wang F. Tang Z. Shao H. Guo J. Tan T. Dong Y. Lin L. Long noncoding RNA HOTTIP cooperates with CCCTC-binding factor to coordinate HOXA gene expression. Biochem. Biophys. Res. Commun. 2018 500 4 852 859 10.1016/j.bbrc.2018.04.173 29698677
    [Google Scholar]
  41. Liu R. Li Z. Song E. Hu P. Yang Q. Hu Y. Liu H. Jin A. LncRNA HOTTIP enhances human osteogenic BMSCs differentiation via interaction with WDR5 and activation of Wnt/β-catenin signalling pathway. Biochem. Biophys. Res. Commun. 2020 524 4 1037 1043 10.1016/j.bbrc.2020.02.034 32067741
    [Google Scholar]
  42. Zeng X. Dong Q. Liu Q. Tan W.J. Liu X.D. LncRNA HOTTIP facilitates osteogenic differentiation in bone marrow mesenchymal stem cells and induces angiogenesis via interacting with TAF15 to stabilize DLX2. Exp. Cell Res. 2022 417 2 113226 10.1016/j.yexcr.2022.113226 35644412
    [Google Scholar]
  43. Shang A. Wang W. Gu C. Chen C. Zeng B. Yang Y. Ji P. Sun J. Wu J. Lu W. Sun Z. Li D. Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils. J. Exp. Clin. Cancer Res. 2019 38 1 411 10.1186/s13046‑019‑1394‑6 31533774
    [Google Scholar]
  44. Liu J. Hu H.B. Liu Y.M. Li F.X. Zhang L.P. Liao Z.M. LncRNA HOTTIP promotes the proliferation and invasion of ovarian cancer cells by activating the MEK/ERK pathway. Mol. Med. Rep. 2020 22 5 3667 3676 10.3892/mmr.2020.11452 33000231
    [Google Scholar]
  45. Tan C. Liu W. Zheng Z.H. Wan X.G. LncRNA HOTTIP inhibits cell pyroptosis by targeting miR‐148a‐3p/AKT2 axis in ovarian cancer. Cell Biol. Int. 2021 45 7 1487 1497 10.1002/cbin.11588 33710684
    [Google Scholar]
  46. Dong Y.J. Feng W. Li Y. HOTTIP-miR-205-ZEB2 axis confers cisplatin resistance to ovarian cancer cells. Front. Cell Dev. Biol. 2021 9 707424 10.3389/fcell.2021.707424 34322490
    [Google Scholar]
  47. Zhang S. Ma Q. Wu X. Chen P. LncRNA hottip promotes ovarian cancer cell invasion and metastasis by stabilizing HIF-1α in the anoxic cellular microenvironment. Acta Endocrinol. 2022 18 3 263 270 10.4183/aeb.2022.263 36699159
    [Google Scholar]
  48. Khatoon E. Parama D. Kumar A. Alqahtani M.S. Abbas M. Girisa S. Sethi G. Kunnumakkara A.B. Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy. Life Sci. 2022 306 120827 10.1016/j.lfs.2022.120827 35907493
    [Google Scholar]
  49. Xu H. Lu M. Liu Y. Ren F. Zhu L. Identification of a pyroptosis-related long non-coding RNA Signature for prognosis and its related ceRNA regulatory network of ovarian cancer. J. Cancer 2023 14 16 3151 3168 10.7150/jca.88485 37859811
    [Google Scholar]
  50. Yang Y. Qian J. Xiang Y. Chen Y. Qu J. The prognostic value of long noncoding RNA HOTTIP on clinical outcomes in breast cancer. Oncotarget 2017 8 4 6833 6844 10.18632/oncotarget.14304 28036281
    [Google Scholar]
  51. Sun Y. Zeng C. Gan S. Li H. Cheng Y. Chen D. Li R. Zhu W. LncRNA HOTTIP-mediated HOXA11 expression promotes cell growth, migration and inhibits cell apoptosis in breast cancer. Int. J. Mol. Sci. 2018 19 2 472 10.3390/ijms19020472 29415429
    [Google Scholar]
  52. Gao W. Wu X.L. Li D.Z. Liu H.D. HOTTIP participates in mammary cancer by promoting cell proliferation via PI3K/AKT pathway. Eur. Rev. Med. Pharmacol. Sci. 2018 22 13 4181 4187 30024606
    [Google Scholar]
  53. Han S. Jin X. Liu Z. Xing F. Han Y. Yu X. He G. Qiu F. The long noncoding RNA HOTTIP promotes breast cancer cell migration, invasiveness, and epithelial–mesenchymal transition via the Wnt–β-catenin signaling pathway. Biochem. Cell Biol. 2019 97 5 655 664 10.1139/bcb‑2018‑0313 30676763
    [Google Scholar]
  54. Han L. Yan Y. Zhao L. Liu Y. Lv X. Zhang L. Zhao Y. Zhao H. He M. Wei M. LncRNA HOTTIP facilitates the stemness of breast cancer via regulation of miR‐148a‐3p/WNT1 pathway. J. Cell. Mol. Med. 2020 24 11 6242 6252 10.1111/jcmm.15261 32307830
    [Google Scholar]
  55. Abdelaleem O.O. Shaker O.G. AbdelHafez M.N. Abdelghaffar N.K. Eid H.M. Zaidan M. Khalefa A.A. Ahmed N.A. Hemeda N.F. Zaki O.M. Awaji A.A.A. Mohammed S.R. The influence of rs1859168 polymorphism on serum expression of HOTTIP and its target miR-615-3p in Egyptian patients with breast cancer. Biomolecules 2021 11 5 733 10.3390/biom11050733 34069089
    [Google Scholar]
  56. Liu F Effect of lncRNA HOTTIP on proliferation, migration and invasion of cervical cancer cells. Military Medical Sciences 2015 443-447 452
    [Google Scholar]
  57. Chuntao W. Anxing G. Hongyan W. Xueyan Z. Sheng Y. Hongxiang Y. The association between cervical lesions of different grades and lncRNA HOTTIP and H19 single nucleotide polymorphisms. China Oncology 2022 32 324 334
    [Google Scholar]
/content/journals/cmm/10.2174/0115665240336515241124151446
Loading
/content/journals/cmm/10.2174/0115665240336515241124151446
Loading

Data & Media loading...


  • Article Type:
    Review Article
Keywords: Gynecologic cancers ; lncRNAs ; HOTTIP ; targeted therapy
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test